aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
XTuit Pharmaceuticals, founded in 2011 and based in Waltham, Massachusetts, focuses on developing pharmaceutical preparations for diagnosing and treating oncological, tumor, and inflammatory diseases. The company aims to revolutionize cancer therapy by targeting the tumor microenvironment, offering novel approaches to improve patient outcomes.
XTuit Pharmaceuticals has made significant strides in cancer treatment innovation, impacting the pharmaceutical industry with its targeted therapies. The company's work has garnered attention for its potential to enhance the effectiveness of cancer treatments, positioning it as a notable player in the oncology field.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Pharmaceuticals
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was XTuit Pharmaceuticals founded?
XTuit Pharmaceuticals was founded in 2011.
Where is XTuit Pharmaceuticals’s headquarters located?
XTuit Pharmaceuticals’s headquarters is located in Cambridge, MA, US.
When was XTuit Pharmaceuticals’s last funding round?
XTuit Pharmaceuticals’s most recent funding round was for $22M (USD) in June 2015.
How many employees does XTuit Pharmaceuticals have?
XTuit Pharmaceuticals has 30 employees as of Feb 5, 2024.
How much has XTuit Pharmaceuticals raised to-date?
As of July 05, 2023, XTuit Pharmaceuticals has raised a total of $26M (USD) since Jun 11, 2015.
Add Comparison
Total Raised to Date
$26M
USD
Last Update Jun 11, 2015
Last Deal Details
$22M
USD
Jun 11, 2015
Series A
Total Employees Over Time
30
As of Feb 2024
XTuit Pharmaceuticals Address
700 Main Street
Cambridge,
Massachusetts
MA 02139
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts